Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 770 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Sickle Cell Disorder Clear all
Recruiting Phase 2 Interventional Accepts healthy volunteers

Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET

NCT05583721
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
[13N]NH3, Lexiscan, Positron emission tomography
Drug · Diagnostic Test
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years to 21 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 21, 2026, 6:55 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Evaluation of HemoTypeSC as a Novel Rapid Test for Point-of-Care Screening for Sickle-Cell Disease, Hemoglobin C Disease, and Carrier Status in Low-Resource Settings

NCT03619798
View directory record Official record
Conditions
Diagnoses Disease
Interventions
HemoTypeSC
Device
Lead sponsor
Silver Lake Research Corporation
Industry
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Azusa, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Jul 21, 2026, 6:55 PM EDT
Completed No phase listed Observational

Stigma, Self-management, & Quality of Life in SCD

NCT03488264
View directory record Official record
Conditions
Sickle Cell Disease, Quality of Life, Stigma, Social, Disease Self-Management
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Jul 21, 2026, 6:55 PM EDT
Completed Not applicable Interventional

Laboratory-based Hypnosis Intervention on Pain Responsivity in Adolescents With Sickle Cell Disease

NCT02987725
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Hypnosis, Attention Control
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
12 Years to 21 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Jul 21, 2026, 6:55 PM EDT
Recruiting Not applicable Interventional

Trans-auricular Nerve Stimulation as an Innovative Approach to the Treatment of Pain in Pediatric Patients Suffering From Sickle Cell Disease

NCT07090668
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
tAN device
Device
Lead sponsor
Emory University
Other
Eligibility
7 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Jul 21, 2026, 6:55 PM EDT
Completed Not applicable Interventional

The Feasibility of the PAINReportIt Guided Relaxation Intervention-Outpatient

NCT02729363
View directory record Official record
Conditions
Sickle Cell Disease, Stress, Pain
Interventions
Guided Relaxation video clip, Sickle Cell Disease Experience Discussion
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Jul 21, 2026, 6:55 PM EDT
Completed Phase 2 Interventional

Research Study Investigating How Well NDec Works in People With Sickle Cell Disease

NCT05405114
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
NDec - oral decitabine-tetrahydrouridine, HU - Hydroxyurea, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
53
States / cities
Mobile, Alabama • Los Angeles, California • Oakland, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 21, 2026, 6:55 PM EDT
Completed Not applicable Interventional Results available

Self-Management for Youth and Families Living With SCD - SMYLS

NCT03585543
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Voice Crisis Alert V2
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
8 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Jul 21, 2026, 6:55 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Establishment of Functional MRI Imaging Parameters for Use in the Evaluation of Sickle Cell Disease

NCT02445144
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
Not listed
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
2
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2020 · Synced Jul 21, 2026, 6:55 PM EDT
Completed Not applicable Interventional Results available

Evaluation of the AMICUS RBCx System in Sickle Cell Patients

NCT02372877
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
Amicus Red Cell Exchange in SCD patients
Device
Lead sponsor
Fenwal, Inc.
Industry
Eligibility
6 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
6
States / cities
Phoenix, Arizona • Detroit, Michigan • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Jul 21, 2026, 6:55 PM EDT
Completed Phase 2 Interventional Results available

Inhaled Mometasone to Reduce Painful Episodes in Patients With Sickle Cell Disease

NCT02061202
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Mometasone Furoate, Placebo
Drug
Lead sponsor
Jeffrey Glassberg
Other
Eligibility
15 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2019 · Synced Jul 21, 2026, 6:55 PM EDT
Completed No phase listed Observational

Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients

NCT03609827
View directory record Official record
Conditions
Hematologic Malignancies, Nonmalignant Diseases, Immunodeficiencies, Hemoglobinopathies, Genetic Inborn Errors of Metabolism, Fanconi's Anemia, Thalassemia, Sickle Cell Disease
Interventions
Melphalan
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2021 · Synced Jul 21, 2026, 6:55 PM EDT
Completed Phase 4 Interventional

Voxelotor Sickle Cell Exercise Study

NCT04581356
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
Voxelotor
Drug
Lead sponsor
Elizabeth Yang, MD, PhD
Other
Eligibility
12 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Jul 21, 2026, 6:55 PM EDT
Recruiting Phase 2 Interventional

Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin

NCT07175051
View directory record Official record
Conditions
Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), Albuminuria
Interventions
Empagliflozin (oral)
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jul 21, 2026, 6:55 PM EDT
Completed Phase 1 Interventional

A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Participants With Sickle Cell Disease (SCD).

NCT04912869
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Crovalimab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Jul 21, 2026, 6:55 PM EDT
Active, not recruiting Not applicable Interventional

Therapeutic Response Evaluation and Adherence Trial (TREAT)

NCT02286154
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
Hydroxyurea
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Months to 21 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Jul 21, 2026, 6:55 PM EDT
Completed Not applicable Interventional

Enhancing Use of Hydroxyurea In Sickle Cell Disease Using Patient Navigators

NCT02197845
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Patient Navigator, Recruitment into Specialty Care
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
15 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Jul 21, 2026, 6:55 PM EDT
Terminated Not applicable Interventional Results available

Designing an Implementation Strategy for Delivering Routine Mental Health Screening and Treatment

NCT04587661
View directory record Official record
Conditions
Sickle Cell Disease, Depression, Anxiety
Interventions
off-the-shelf digital CBT, adapted digital CBT
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
16 Years to 35 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Jul 21, 2026, 6:55 PM EDT
Completed Not applicable Interventional

The Feasibility of the Pray Until Something Happens (PUSH) Intervention-OUTPATIENT

NCT06580067
View directory record Official record
Conditions
Sickle Cell Disease, Stress, Pain
Interventions
Pray Until Something Happens (PUSH), Self-monitoring
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Jul 21, 2026, 6:55 PM EDT
Completed Phase 2 Interventional Results available

Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload

NCT01186419
View directory record Official record
Conditions
Transfusional Iron Overload, Beta-thalassemia
Interventions
SPD602 (FBS0701, SSP-004184)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 60 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Oakland, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Jul 21, 2026, 6:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Acute Kidney Injury in Patients With Sickle Cell Disease

NCT03105271
View directory record Official record
Conditions
Sickle Cell Disease, Kidney Injury, Kidney Diseases, Kidney Disease, Chronic
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Year to 25 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 6, 2022 · Synced Jul 21, 2026, 6:55 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Hydroxyurea for Children and Young Adults With Sickle Cell Disease and Pulmonary Hypertension

NCT00350844
View directory record Official record
Conditions
Sickle Cell Disease, Pulmonary Hypertension
Interventions
Hydroxyurea
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
10 Years to 25 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Jul 21, 2026, 6:55 PM EDT
Completed Phase 4 Interventional

A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT

NCT03176849
View directory record Official record
Conditions
Vitamin D Deficiency, Stem Cell Transplant Complications, Pediatric Cancer, Blood Disorder, Pediatric Acute Myeloid Leukemia, Pediatric Acute Lymphoid Leukemia, Myelodysplastic Syndromes, Sickle Cell Anemia in Children, Aplastic Anemia, Thalassemia in Children
Interventions
Vitamin D3, Standard Vitamin D3 Supplementation
Dietary Supplement
Lead sponsor
Phoenix Children's Hospital
Other
Eligibility
1 Year to 25 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Jul 21, 2026, 6:55 PM EDT
Recruiting Not applicable Interventional

Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain

NCT06374238
View directory record Official record
Conditions
Pain, Sickle Cell Disease
Interventions
CBT+ Health coach, CBT w/o Health Coach ( self-guided), Usual Care
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
16 Years to 30 Years
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
14
States / cities
Mobile, Alabama • Los Angeles, California • Hartford, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jul 21, 2026, 6:55 PM EDT